https://www.selleckchem.com/pr....oducts/fingolimod.ht
Introduction There are limited data on repeated basal cell cancer (BCC) occurrences among patients with inflammatory bowel disease (IBD), especially the impact of continuing immunosuppressive medications. Methods We conducted a retrospective cohort study of 54,919 patients with IBD followed in the Veterans Affairs Healthcare System. We identified patients who had an incident BCC after their IBD diagnosis. We defined patients' exposure based on their IBD medications use as follows (i) only aminosalicylate (5-ASA) use, (ii) only active
Like
Comment
Share
